PCAR 019

Drug Profile

PCAR 019

Alternative Names: Anti-CD19 CAR T cells - PersonGen BioTherapeutics; Anti-CD19 CAR-transduced T cells - PersonGen BioTherapeutics; PCAR019

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator PersonGen Biomedicine
  • Class Antineoplastics; CAR-T cell therapies; Immunotherapies
  • Mechanism of Action CD19 antigen modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Leukaemia; Lymphoma

Most Recent Events

  • 01 Oct 2016 PersonGen BioTherapeutics initiates a phase-I/II trial in Lymphoma and Leukaemia (In adults, Second-line therapy or greater) in China (Parenteral) (NCT02819583)
  • 05 Jul 2016 PersonGen Biomedicine plans a phase I/II trial for Cancer in China (NCT02819583)
  • 01 Jul 2016 Phase-I/II clinical trials in Lymphoma and Leukaemia (In adolescents, In adults, Second-line therapy or greater) in China (Parenteral) (NCT02851589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top